Iotroxate (Meglumine)

Drug #388

Iotroxate (Meglumine) is iodinated, water soluble radiological contrast agent for intravenous cholangiography and cholecystography. Chemically Iotroxate (Meglumine) is N-methylglucamino-3,3-(3, 6, 9-trioxaundecanedioyldi-imino) bis (2, 4, 6-tri-iodobenzoate). Iotroxate (Meglumine) is prepared by chemical synthesis and not available in any combination preparations.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Iodinated Organic Compounds.

It belongs to Radiopaque Agents pharmacological group on the basis of mechanism of action. It is also classified under Diagnostic Aids .

Molecular Weight: 1606 · Solubility in Water: high · Non-proprietary name: Iotroxate (Meglumine).

Molecular structure of Iotroxate (Meglumine)

Pharmacokinetics

Absorption: Iotroxate (Meglumine) has an oral bioavailability is 15.5% (±4.5%).

Distribution: Iotroxate (Meglumine) has a plasma protein binding is 60-90%.

Elimination: it is metabolised via small amount, plasma half-life is 80 min, renal excretion is < 10%.

Indications

Iotroxate (Meglumine) is primarily indicated in conditions like Cholangiography, Cholecystography, Failure of oral cholecystography, Postcholicystectomy biliary symptoms, Suspected cholidocholithiasis in non-icterics.

Contraindications

Iotroxate (Meglumine) is contraindicated in conditions like Asthma, Myeloma, Atopy, Hypersensitivity.

Dosage

Iotroxate (Meglumine)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
10.5 %	10.5 %	—	IV Inf	Once,upto 15 min.,as required
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown5 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Iotroxate (Meglumine) in overdosage may give rise to further complications which include Nephrotoxicity , Hepatotoxicity , Hepatotoxicity , Sickle crises in sicklers , Hypertensive crises in existing pheochromocytoma.

Iotroxate (Meglumine) produces potentially life-threatening effects which include Anaphylactoid reactions , Bronchospasm , Bronchospasm, Acute Renal Failure , Angioneurotic edema, Acute renal failure, Obstructive nephropathy, Angioneurotic edema, Circulatory collapse, circulatory collapse. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Iotroxate (Meglumine) are Acute renal failure.

Iotroxate (Meglumine) is known to cause more or less tolerable side effects which are usually transient. These include Faintness , Flushing, Headache, Nausea and vomiting, Restlessness, Sedation .

Warnings / Precautions

Iotroxate should be administered with great caution in patients with asthma and history of allergy, and should be avoided to patients with known hypersensitivity to iodine or contrast media. Caution is needed in patients with severe hepatic (liver) or renal impairment or who may be at a risk of renal failure. Dehydration patients should have their fluid and electrolyte balance corrected before administration of contrast medium. It should be used with extreme caution in patients with hypertension, cardiac disease, pheochromocytoma, sickle-cell anemia or hypothyroidism. Avoid use during pregnancy.

Interference in Pathology

Iotroxate (Meglumine) may interfere in the diagnosis of Thyroid Function Test , Sulphosalicylic acid test , False +ve result of Urinary Glucose , Test with Cupric Sulphate and prolong various measure of clotting, coagulation cascade .

Available Brands

None recorded.

Storage Conditions

Iotroxate (Meglumine) should be stored IV inf.

Drug Classification

1.14.2 — Radiocontrast media